Objective To analyze the genetic diversity of eight species of Caragana Fabr. in Ordos Plateau. Methods To study the genetic diversity of the eight species with ISSR method. Results The total percentage of polymorphic bands (PPB) of the eight species was up to 100%, which was extremely high and showed an abundant genetic diversity. However, the genetic diversity of different species was not the same. The genetic diversity of C. tibetica, C. korshinskii, C. stenophylla, C. roborovskyi, and C. intermedia was higher, while that of C. opulens and C. purdomii was lower, and that of C. brachypoda was the lowest. The analytic results of the Nei′s gene diversities and the Shannon′s information index were similar. Different species could be differentiated through UPGMA method and characteristic banding pattern of ISSR. Conclusion ISSR Molecular marker could be used in molecular authentication and hereditary background study of the species of Caragana Fabr. These results provide the scientific basis of developing effective protection measures for these species.

Objective To study the application value of iodixanol in gemstone spectral imaging with low CT dosage.Methods Forty hundred and twenty -six cancer patients with normal kidney function were selected .All of them underwent enhanced gemstone spectral CT scan with low dosage .They were individed into two groups with random number table,including observation group(n=213) and control group(n=213).The observation group was injected isotonic iodixanol ( 270 mgI/mL ) intravenously , while the control group was injected hypertronic iohexol (350mgI/mL) intravenously.With the same injection speed,the acute adverse reaction within 1h and delayed adverse reaction between 1h～7d were recorded.Meanwhile,the changes of Scr and Ccr ,the occurrence rate of contrast -induced nephropathy(CIN) and short -term prognosis were also recorded.Results Fifty-three patients occurred acute adverse reaction,among them 18 cases(8.45％) were in the observation group,35 cases(16.43％) were in the control group,there was statistically significant difference between the two groups (χ2 =10.791,P<0.05).Three patients(1.50％) of the control group occurred delayed adverse reaction ,no one was in the observation group .The adverse reaction disappeared after some time .Two kinds of contrast media caused slight increase of Scr and decrease of Ccr,but there were no statistically significant differences between them (all P>0.05).Conclusion The intrave-nous injection of iodixanol can reduce the occurrence of acute adverse reaction ,will not increase the incidence of CIN . It can be used safely .

Objective:To evaluate the efficacy and prognostic factors of 125I seeds implantation for primary hepatocellular carcinoma. Methods:From December 2011 to January 2021, 102 primary hepatocellular carcinoma patients (86 males, 16 females; median age 61 years) who underwent 125I seeds implantation from 5 hospitals in China were enrolled in this retrospective study. Local progression-free survival (LPFS), overall survival (OS) and the prognostic factors were analyzed. Kaplan-Meier method was used to draw the distribution curve of survival time, and LPFS rate and OS rate were calculated. Log-rank test and Cox regression were used to analyze the influencing factors of survival. Results:The median follow-up time was 38 months until April 2021. The local control rate was 96.1%(98/102). The 1-, 3- and 5-year LPFS rate were 61.3%, 25.5% and 12.7%, and the 1-, 3- and 5-year OS rate were 73.9%, 39.1% and 22.6%, respectively. There were 75 patients with progressive disease, including 42 patients with intrahepatic recurrence and metastasis after seed implantation, and 55 patients died. Multivariate analyses showed that short-term efficacy complete response (CR) (hazard ratio ( HR)=0.34, 95% CI: 0.20-0.58) was protective factor related to LPFS; short-term efficacy CR ( HR=0.25, 95% CI: 0.13-0.47) was the protective factors related to OS; Barcelona clinic liver cancer (BCLC) C stage ( HR=2.33, 95% CI: 1.27-4.27), intrahepatic progression and extrahepatic metastasis ( HR=3.18, 95% CI: 1.28-7.86; HR=3.23, 95% CI: 1.27-8.21) were independent risk factors related to OS. No sever adverse effects were observed. Conclusions:125I seeds implantation is safe and effective for the treatment of primary hepatocellular carcinoma. BCLC stage, short-term efficacy and post-implantation progression are independent factors related to survival time.